Clinical impact of follicular oncocytic (Hurthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma

被引:18
|
作者
Wenter, Vera [1 ]
Albert, Nathalie L. [1 ]
Unterrainer, Marcus [1 ]
Ahmaddy, Freba [1 ]
Ilhan, Harun [1 ,2 ,3 ]
Jellinek, Annamirl [1 ]
Knoesel, Thomas [4 ]
Bartenstein, Peter [1 ,2 ,3 ]
Spitzweg, Christine [2 ,3 ,5 ]
Lehner, Sebastian [1 ]
Todica, Andrei [1 ,2 ,3 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Nucl Med, Univ Hosp, Marchioninistr 15, D-81377 Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Comprehens Canc Ctr CCC LMU, Univ Hosp, Munich, Germany
[3] Ludwig Maximilians Univ Munchen, Interdisciplinary Ctr Thyroid Carcinoma ISKUM, Univ Hosp, Munich, Germany
[4] Ludwig Maximilians Univ Munchen, Fac Med, Inst Pathol, Univ Hosp, Munich, Germany
[5] Ludwig Maximilians Univ Munchen, Dept Internal Med 4, Univ Hosp, Munich, Germany
关键词
Hurthle cell carcinoma; Oncocytic; oxyphilic follicular carcinoma; Follicular thyroid cancer; Radioablation; ASSOCIATION GUIDELINES; RADIOACTIVE IODINE; FOLLOW-UP; CANCER; PROGNOSIS; SURVIVAL; NODULES; MANAGEMENT; DIAGNOSIS; NEOPLASMS;
D O I
10.1007/s00259-020-04952-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose There are controversial debates if patients with Hurthle cell carcinoma, also known as oxyphilic or oncocytic cell follicular thyroid carcinoma, have a poorer outcome. In this study, we systematically evaluated the clinical outcome in a large patient cohort following thyroidectomy and initial I-131 radioactive iodine therapy (RIT). Methods We retrospectively evaluated a total of 378 patients with diagnosed oncocytic follicular Hurthle cell carcinoma (OFTC) (N = 126) or with classical follicular thyroid carcinoma (FTC) (N = 252). Patients received thyroidectomy and complementary I-131 RIT. Clinical data regarding basic demographic characteristics, tumor grade, persistent disease and recurrence during follow-up, and disease-free, disease-specific, and overall survival were collected during follow-up of 6.9 years (interquartile range 3.7; 11.7 years). Univariate and multivariate analyses were used to identify factors associated with disease-related and overall survival. Results Before and after matching for risk factors, recurrence was significantly more frequently diagnosed in OFTC patients during follow-up (17% vs. 8%;pvalue 0.037). Likewise, OFTC patients presented with a reduced mean disease-free survival of 17.9 years (95% CI 16.0-19.8) vs. 20.1 years (95% CI 19.0-21.1) in FTC patients (pvalue 0.027). Multivariate analysis revealed OFTC (HR 0.502; 95% CI 0.309-0.816) as the only independent prognostic factor for disease-free survival. Distant metastases of OFTC patients were significantly less iodine-avid (pvalue 0.014). Mean disease-specific and overall survival did not differ significantly (pvalue 0.671 and 0.687) during follow-up of median 6.9 years (3.7; 11.7 years). Conclusions Our study suggests that recurrence is more often seen in OFTC patients. OFTC patients have a poorer prognosis for disease-free survival. Thus, OFTC and FTC behave differently and should be categorized separately. However, patients suffering from OFTC present with the same overall and disease-specific survival at the end of follow-up indifferent to FTC patients after initial RIT.
引用
收藏
页码:449 / 460
页数:12
相关论文
共 50 条
  • [1] Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
    Vera Wenter
    Nathalie L. Albert
    Marcus Unterrainer
    Freba Ahmaddy
    Harun Ilhan
    Annamirl Jellinek
    Thomas Knösel
    Peter Bartenstein
    Christine Spitzweg
    Sebastian Lehner
    Andrei Todica
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 449 - 460
  • [2] Comparison of clinical characteristics of patients with follicular thyroid carcinoma and Hurthle cell carcinoma
    Ernaga Lorea, Ander
    Migueliz Bermejo, Iranzu
    Anda Apinaniz, Emma
    Pineda Arribas, Javier
    Toni Garcia, Marta
    Martinez de Esteban, Juan Pablo
    Insausti Serrano, Ana Maria
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2018, 65 (03): : 136 - 142
  • [3] Follicular and Hurthle Cell Thyroid Carcinoma: Comparison of Recurrence and Survival
    Ranganath, Rohit
    Wang, Laura Y.
    Hay, Ashley
    Migliacci, Jocelyn C.
    Tuttle, Michael
    Ghossein, Ronald A.
    Ganly, Ian
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (04) : S69 - S69
  • [4] Follicular and Hurthle cell carcinoma of the thyroid gland
    Phitayakorn, Roy
    McHenry, Christopher R.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 15 (03) : 603 - +
  • [5] FOLLICULAR AND HURTHLE CELL-CARCINOMA OF THE THYROID
    COOPER, DS
    SCHNEYER, CR
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1990, 19 (03) : 577 - 591
  • [6] Poorly Differentiated Oncocytic (Hurthle Cell) Follicular Carcinoma: An Institutional Experience
    Bai, S.
    Baloch, Z. W.
    Montone, K. T.
    LiVolsi, V. A.
    LABORATORY INVESTIGATION, 2013, 93 : 303A - 303A
  • [7] HURTHLE CELL FOLLICULAR CARCINOMA OF THE THYROID-GLAND
    GENTILE, RD
    WEBER, SC
    TRUONG, LD
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1985, : 108 - 108
  • [8] Poorly Differentiated Oncocytic (Hurthle Cell) Follicular Carcinoma: an Institutional Experience
    Bai, Shuting
    Baloch, Zubair W.
    Samulski, Teresa D.
    Montone, Kathleen T.
    LiVolsi, Virginia A.
    ENDOCRINE PATHOLOGY, 2015, 26 (02) : 164 - 169
  • [9] Do Small Oncocytic Follicular Carcinoma/Hurthle Cell Carcinoma Exist? An Institutional Experience
    Samulski, T.
    Shuting, B.
    LiVolsi, V.
    Montone, K.
    Baloch, Z.
    MODERN PATHOLOGY, 2013, 26 : 312A - 312A
  • [10] Poorly Differentiated Oncocytic (Hurthle Cell) Follicular Carcinoma: An Institutional Experience
    Bai, S.
    Baloch, Z. W.
    Montone, K. T.
    LiVolsi, V. A.
    MODERN PATHOLOGY, 2013, 26 : 303A - 303A